Wacker and Expression Manufacturing want to offer clients with an end-to-end, optimized solution for viral vector development and production.

US biotech Lexeo Therapeutics has secured $80 million from a private placement, giving the company enough capital to push ...

Delandistrogene moxeparvovec, a gene therapy for Duchenne muscular dystrophy (DMD), showed high dystrophin expression and a ...

Complex traits are influenced by genes and the environment, but especially the latter is difficult to pin down. This important study uses C. elegans to demonstrate that non-genetic differences in gene ...

FDA places clinical hold of RP-A501 for the treatment of patients with Danon disease due to a patient death. Click here to ...

(“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, announced that its research ...

D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment ...

New studies stemming from the Armamentarium consortium outline findings that advance tools based on Adeno-associated virus ...

Muscimol, a GABA-A (GABAA) receptor agonist, enhances GABA's inhibitory effect on neuronal activity by activating GABAA ...

This study identifies 53BP1 as an interaction partner of GMCL1 (a likely CUL3 substrate receptor). The study seeks to link this finding to regulation of the mitotic surveillance pathway and paclitaxel ...

Long-term data from Genethon’s GNT0004 Phase 1/2 trial reveal sustained motor function in boys with Duchenne muscular ...